Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science
Two key components of this initiative include the
"Through Innovation Starts Here, Lilly is contributing to a global collaborative culture for idea generation and innovation, helping to build the Lilly pipeline for the future while also providing resources to advance important research and development programs in
Dr. Lundberg made these comments while in
- Lilly has multiple clinical trials underway for new potential medicines across a number of unique areas.
- Lilly participates in the Innovative Medicines Initiative, a public-private collaboration aiming to speed the development of new medicines for patients; Lilly has contributed to 11 projects with more in the pipeline.
- Lilly established the
Centre for Cognitive Neuroscience, an industry-academic consortium and post-doctoral fellowship program focused on increasing the probability of clinical success for potential medicines to treat conditions involving cognitive impairment, such as sleep disorders, Alzheimer's disease and Parkinson's disease.
- Later this spring, Lilly plans to open a new building at its
Erl Wood Research Centerin the United Kingdom. Opened in 1967, Erl Wood was the company's first R&D site outside the United States.
Innovation Fellowship Awards
Lilly's new Innovation Fellowship Awards Program will foster post-doctoral career development through the selection of highly innovative research proposals. Lilly has created this program to broaden post-doctoral scientists' training experiences and better prepare them for a broad range of careers, including in the pharmaceutical industry. The awards establish a pre-competitive academic-industry training partnership where a post-doctoral fellow and academic mentor are paired with a Lilly scientist to provide the industry resources that can enable the advancement of the post-doctoral scientists' research proposal. In 2012, the Lilly Fellowship Award Program will be by invitation only to applicants at academic research centers in
Research Awards Program
The collaborations established under the
Three of the collaborative research projects selected for funding in 2011 under the
Department of Neurobiology, University Hospital Copenhagen, Denmark: two-year program that will explore the potential expression and function of novel receptor variants in the brain to generate more robust findings regarding their roles in cognition, particularly as they relate to schizophrenia and Alzheimer's disease, which could lead to the advancement of new molecules into clinical development. Institute of Neuroscience, Alicante, Spain: two-year program that will advance the understanding of the neurobiology of schizophrenia in order to help manage cognitive impairment and treat negative symptoms of the disease. Indiana University School of Medicine, Indianapolis: two-year program to study the roles played by distinct types of signals associated with chronic pain disorders with the long-term goal of discovering new treatments for neurological disorders and pain that deliver better patient outcomes. Indianapolisis the site of Lilly's global corporate and R&D headquarters.
"This collaboration with Lilly allows us to take our research in this important area of cognition one step further in an effort to generate data that could help inform future clinical studies in schizophrenia and Alzheimer's disease," said
"We are excited this project was accepted and are eager to begin this important work that we believe has the potential to inform how we develop better medicines for treating neurological disorders and pain," said
Currently, Lilly is visiting academic institutions worldwide to invite them to participate in the
Notes to Editors
Interviews on request with:
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in
News Provided by Acquire Media